1.
JACC Case Rep
; 29(13): 102379, 2024 Jul 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38827265
RESUMO
RASopathies cause nonsarcomeric hypertrophic cardiomyopathy via dysregulated signaling through RAS and upregulated mitogen-activated protein kinase activity. We provide the first report of the successful treatment of an adult with RAF1-associated hypertrophic cardiomyopathy using trametinib, a MEK inhibitor.